Download full report with analyst certification and important disclosures
May 19 2020, 07:15 IST/BST
UDG Healthcare plc
30% relative valuation gap to US peers provides opportunity
- Sectors : Pharma and healthcare
- Companies : UDG Healthcare plc
DAVY VIEW
UDG delivered an excellent set of H1 20 results and, although backward looking, these should prove indicative of the strength of its operating model once current disruptions ease. In-field activities in Ashfield could start recovering this month and Sharp is also seeing incremental improvements. More importantly, we believe mid-term demand for UDG’s services remains firmly intact. We believe the stock is now fundamentally mispriced, trading at a 30% relative valuation discount versus US peers. A conference call will take place at 08.30.
